Articles written by Vandana Singh - Benzinga

Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast

|Doximity shares surge 37% after strong Q3 results, with net income up 57% to $75.2M. Analysts raise price targets as the company boosts FY25 guidance.

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

|Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

|CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

Why Is Canada-Based Cannabis Firm Canopy Growth Stock Trading Lower On Friday?

|Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025

|Avantor's Q4 net sales missed estimates, but adjusted EPS beat expectations. The company projects 2025 organic revenue growth and stronger free cash flow.

Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years

|On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data

|Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

|Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

|Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.

Why Is Zimmer Biomet Stock Trading Lower On Thursday?

|Zimmer Biomet beat Q4 estimates with $2.02 billion in sales and $2.31 EPS.

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

|Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions

|IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence.

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

|Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

|Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans.

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China

|AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth.

EXCLUSIVE: Intelligent Bio Solutions Expects To Record Increased Profitability In Q2 On Higher-Margin Sales

|Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

|Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

|Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

|Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

|Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.